Endometriosis: An Inflammatory Disease That Requires New Therapeutic Options

Donnez, Jacques; Cacciottola, Luciana

doi:10.3390/ijms23031518

Cited by 20 publications

(22 citation statements)

References 12 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are studies that show markedly increased values of serum VEGF in patients with endometriosis, compared with controls. Our results indicate that Desogestrel treatment reduces VEGF serum levels in patients with endometriosis but with no statistically significant value [38][39][40].…”

Section: Figure 2 -Endometriosis Without Treatment: (A) Ovarian Endom...mentioning

confidence: 94%

Hormonal, apoptotic, proliferative and inflammatory markers’ expression in Desogestrel-treated women with ovarian endometriosis

Matasariu

Lozneanu²,

Dumitrascu³

et al. 2022

Rom J Morphol Embryol

View full text Add to dashboard Cite

Endometriosis is a relatively frequent pathology in gynecological practice. We performed an analysis to demonstrate the molecular changes that occur in endometriosis synthetic progestin-treated patients, hoping to sketch a possible pathophysiological pathway that will help us to better understand and treat this debilitating disease. We conducted a prospective study that included a group of 40 women, evaluated in our hospital between 2020-2021. We evaluated immunohistochemical tissue expression of estrogen receptor (ER), progesterone receptor (PR), B-cell lymphoma 2 (Bcl-2) protein, Ki-67, and serum levels of osteopontin (OPN) and vascular endothelial growth factor (VEGF) in patients with ovarian endometrioma with and without progestin treatment. Our study revealed that Desogestrel treatment increases OPN serum levels, PR and Bcl-2 tissue expression and reduces VEGF serum levels and Ki-67 tissue expression. The results we have obtained are very interesting because the serum levels of OPN seem to be more influenced by progestin treatment, than by endometriosis itself. The study we have conducted gives a molecular complex view of what endometriosis represents and on how Desogestrel treatment works.

show abstract

Section: Figure 2 -Endometriosis Without Treatment: (A) Ovarian Endom...mentioning

confidence: 94%

Hormonal, apoptotic, proliferative and inflammatory markers’ expression in Desogestrel-treated women with ovarian endometriosis

Matasariu

Lozneanu²,

Dumitrascu³

et al. 2022

Rom J Morphol Embryol

View full text Add to dashboard Cite

show abstract

“…According to Bulun et al 11 , 12 and Yilmaz and Bulun, 13 the fact that endometriotic stromal cells are unable to produce progesterone-induced paracrine factors may be due to a lack of PR-B. 14 …”

Section: Drawbacks Of Current Endometriosis Therapiesmentioning

confidence: 99%

“…Although GnRH agonists may be able to treat the symptoms of endometriosis, these drugs also have serious drawbacks, 2 , 4 , 8 , 14 , 15 including: Delivery by injection. Various GnRH agonists like leuprolide acetate, goserelin and triptorelin need to be injected monthly or quarterly.…”

Section: Drawbacks Of Current Endometriosis Therapiesmentioning

confidence: 99%

Profile of Linzagolix in the Management of Endometriosis, Including Design, Development and Potential Place in Therapy: A Narrative Review

Donnez¹,

Cacciottola²,

Squifflet³

et al. 2023

DDDT

Self Cite

View full text Add to dashboard Cite

Estrogens play a critical role in the pathogenesis of endometriosis and it is logical to assume that lowering estradiol levels with oral gonadotropin-releasing hormone (GnRH) antagonists may prove effective, especially in women who fail to respond to progestogens. Indeed, due to progesterone resistance, oral contraceptives and progestogens work well in two-thirds of women suffering from endometriosis, but are ineffective in 33% of women. Oral GnRH antagonists have therefore been evaluated for management of premenopausal women with endometriosis-associated pelvic pain. The first publication on these drugs reported the efficacy of elagolix. The present paper is a narrative review of linzagolix, which is an orally administered GnRH receptor antagonist with low pharmacokinetic/pharmacodynamic variability. It binds to and blocks the GnRH receptor in the pituitary gland, resulting in a dose-dependent drop in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) production. This reduction in LH and FSH levels in turn leads to a dose-dependent decline in estrogen. Phase 2 and 3 trials are reviewed and discussed here. There is a place for GnRH antagonists in the management of symptomatic endometriosis, and linzagolix with or without add-back therapy (ABT) is one option that can be used at low doses, avoiding the need for ABT, which is contraindicated in some patients.

show abstract

“…Endometriosis, characterized by the presence of functional endometrium tissues outside the uterus, is known as an inflammatory disease [1]. Although endometriosis is a benign gynecology disease, it affects around 10% of childbearing-age women, resulting in dysmenorrhea, dyspareunia, chronic pelvic pain, infertility and decreased quality of life [2].…”

Section: Introductionmentioning

confidence: 99%

Features of peritoneal dendritic cells in the development of endometriosis

Zheng

Zhao

et al. 2023

Reprod Biol Endocrinol

View full text Add to dashboard Cite

Background Emerging evidence of immunological dysfunction have been described in endometriosis. Dendritic cells (DCs), one of the main antigen-presenting cells, are specialized in the initiation and modulation of the adaptive immune response. Emerging studies demonstrated both endometrial and circulating differences in DCs populations in women with endometriosis. However, the role and mechanism of peritoneal DCs in endometriosis is still unclear. The present study was undertaken to explore the features of peritoneal DCs in the pathogenesis of endometriosis. This study is beneficial to further clarify the cause of endometriosis and provide a new insight into the medical treatment for endometriosis. Methods The study included 12 women with endometriosis and 11 women without endometriosis. The C57BL6 mouse model of endometriosis was established by intraperitoneal injection of endometrial segments. The peritoneal DCs of endometriosis patients and mouse models were analyzed by fluorescence associated cell sorting (FACS) examination. Results Increased cell density of peritoneal DCs were observed in endometriosis patients. Moreover, the proportion of mature DCs (mDCs, CD80highCD1alow cells) in the peritoneal DCs was lower whereas the proportion of immature DCs (iDCs, CD80lowCD1ahigh cells) was increased in endometriosis patients. Similarly, the cell density of peritoneal DCs in murine models increased immediately after the injection of endometrial tissues and reached the highest level at 14 days. In addition, the proportion of mDCs (CD11chighCD80high cells) in the peritoneal DCs decreased immediately after the injection of endometrial tissues and then increased with the time until 42 days, but still lower than the control group. In contrast, the proportion of iDCs (CD11chighCD80low cells) in the peritoneal DCs showed the opposite dynamic changes. However, after treated with LPS, the mDCs proportion was significantly increased, leading to lower volume and weight of the endometriosis lesions. Conclusions Increased level of peritoneal DCs facilitated the pathogenesis of endometriosis lesions, especially in the early stage of the disease. Furthermore, peritoneal DCs maturation played an important role in the development of endometriosis.

show abstract

Endometriosis: An Inflammatory Disease That Requires New Therapeutic Options

Abstract: Endometriosis, defined as the presence of endometrium-like tissue outside the uterus, is estimated to affect 10% of women of reproductive age [...]

Cited by 20 publications

References 12 publications

Hormonal, apoptotic, proliferative and inflammatory markers’ expression in Desogestrel-treated women with ovarian endometriosis

Hormonal, apoptotic, proliferative and inflammatory markers’ expression in Desogestrel-treated women with ovarian endometriosis

Profile of Linzagolix in the Management of Endometriosis, Including Design, Development and Potential Place in Therapy: A Narrative Review

Features of peritoneal dendritic cells in the development of endometriosis

Contact Info

Product

Resources

About